Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xenon-containing liposomes
- Development stage
- Preclinical
- Lead developer
- University of Texas Health Science Center at Houston
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Xenon-containing liposomes (Xe-ELIP) are an experimental neuroprotective therapeutic consisting of xenon gas encapsulated within echogenic liposomes. Developed by researchers at The University of Texas Health Science Center at Houston and Zymo Pharmaceuticals, the formulation is designed for intravenous administration with site-specific release triggered by localized ultrasound application. Xenon acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, providing neuroprotection by preventing glutamate-induced excitotoxicity. Preclinical studies have investigated its efficacy in treating ischemic stroke, subarachnoid hemorrhage, and depression, where it has been shown to activate survival signaling pathways such as AKT/mTOR/BDNF.
- Other names
- Xe-liposomesxenon-loaded echogenic liposomes
02
Targets
NMDAR (Glutamate receptor ionotropic, NMDA)
Beyond the preview
Go deeper on xenon-containing liposomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xenon-containing liposomes.